Active Brain & Nervous System Infection & Immunity

Decoding the targets of brain regulatory T cells

In plain English

AI plain-English summary

The brain’s own anti-inflammatory immune cells—regulatory T cells, or Tregs—are potent drivers of tissue repair, but no one knows exactly what they are targeting. This matters because brain Tregs could be harnessed to treat conditions like multiple sclerosis, stroke, or neurodegeneration, yet their therapeutic potential remains locked. The key missing piece is the identity of the antigens—the molecular targets—that these cells recognise. Without that knowledge, researchers cannot design therapies that selectively activate or expand the protective Treg population. The team has developed scalable methods to identify the entire repertoire of antigens recognised by the brain’s Tregs in mice—a population so small it was previously out of reach. They will then validate the most promising targets in human patients using cerebrospinal fluid samples. If successful, this work would unlock the first complete map of brain Treg targets, enabling precise immune therapies that boost repair without triggering harmful inflammation. It would also provide a blueprint for decoding T cell targets in other tissues, advancing the broader field of antigen discovery.

View original technical description
Brain-resident regulatory T cells (brain Tregs) are potent anti-inflammatory cells capable of driving neuro-protection and neuro-repair across multiple inflammatory and degenerative conditions. The cells have a high therapeutic potential, with the key unknown limiting the clinical exploitation of brain Tregs being the unknown antigenic targets recognised by these cells. The technology and knowledge-base required for identifying the target antigens for T cell receptors (TCRs) are being rapidly developed, although few studies look at the self-reactive Treg population. Recent advances by the applicant groups have enabled these approaches to be scale-able, allowing for the first time the ambition to identify the antigens of an entire T cell repertoire to be imaginable. The small size of the murine brain Treg population, among the smallest tissue T cell population, combined with the proposed iterative multiplexed approaches, make the repertoire-level identification aim feasible for the first time. We can further validate homologous antigen targets in human patients, using cerebral spinal fluid samples and cutting-edge antigen- led screening. This project will give key insights to the nature of the Treg TCR repertoire, potentiate brain Treg exploitation, and unlock repertoire- scale TCR target identification for the broader field.

View the original record at the funder ↗

Researchers

Hashem Koohy (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Dissecting the code for regulatory T cell entry into the tissues and differentiation into tissue-resident cells
Preventing and reversing neuroinflammatory brain damage using local expansion of regulatory T cells
Novel approaches to determining the function of tissue-specific regulatory T cells
Genetic control of TCR diversity within the natural regulatory T cell lineage
Cellular and molecular organisation of long-lived immunoregulatory responses within the lung

Original classification

Discovery Award

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.